Cantor Fitzgerald Predicts Lower Earnings for Mesoblast

Mesoblast Limited (NASDAQ:MESO - Free Report) - Cantor Fitzgerald decreased their FY2025 earnings estimates for shares of Mesoblast in a research note issued to investors on Monday, March 31st. Cantor Fitzgerald analyst K. Kluska now forecasts that the company will post earnings of ($0.71) per share for the year, down from their prior forecast of ($0.70). Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Mesoblast's current full-year earnings is ($0.70) per share.

Other research analysts also recently issued research reports about the stock. Piper Sandler reissued an "overweight" rating and set a $24.00 target price (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Jefferies Financial Group cut shares of Mesoblast from a "buy" rating to a "hold" rating in a report on Monday, December 23rd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.00.

Mesoblast Stock Performance

MESO stock traded down $0.22 during midday trading on Wednesday, reaching $11.60. The company's stock had a trading volume of 168,102 shares, compared to its average volume of 298,538. Mesoblast has a 1 year low of $4.60 and a 1 year high of $22.00. The stock has a fifty day simple moving average of $15.85 and a two-hundred day simple moving average of $13.27. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.18 and a current ratio of 1.18.

Remove Ads

Institutional Trading of Mesoblast

Several institutional investors have recently bought and sold shares of the business. Jane Street Group LLC grew its holdings in Mesoblast by 46.4% in the 3rd quarter. Jane Street Group LLC now owns 85,102 shares of the company's stock valued at $695,000 after buying an additional 26,959 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Mesoblast by 22.1% in the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company's stock valued at $133,000 after purchasing an additional 1,213 shares during the period. Ballentine Partners LLC acquired a new position in Mesoblast during the 4th quarter worth $222,000. R Squared Ltd purchased a new stake in Mesoblast during the 4th quarter worth about $30,000. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in Mesoblast in the 4th quarter valued at about $134,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.